ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

AstraZeneca, AbbVie and Abbott side by side

Their registered studies and the programs behind them, as ClinicalTrials.gov shows them and the companies' own pipelines name them. Counts, not rankings: the companies differ in size, so each number is shown beside its share of that company's own programs.

AstraZeneca×AbbVie×Abbott×Three at a time for now; Pro will compare up to ten.

At a glance

Studies each sponsor leads, with the companies grouped under it. Every number opens the studies it counts.

AstraZenecaAbbVieAbbott
studies on the registry4,1972,2511,346
open to participants now29813352
phase 3 studies under way200740
reach primary completion within a year1689025
programswith a study of their own in two years119+5 named only70+8 named onlynone read

Pipeline by phase

Each program once, at the furthest phase its own studies reached. The bar is the share of that company's programs, so a small company and a large one read on the same scale.

Furthest phaseAstraZenecaAbbVieAbbott
Phase 1

AstraZeneca: 25 of its 119 programs at phase 1

  1. AZD4954phase 1
  2. AZD1613phase 1
  3. AZD1390phase 1
  4. Actinium Ac 225-DOTA-Anti-STEAP2 Monoclonal Antibody AZD2284phase 1
  5. ALXN2230phase 1

and 20 more — sign in to see them all

21%

AbbVie: 28 of its 70 programs at phase 1

  1. Anti-CD19-Glucosteroid Receptor Modulator ADC ABBV-31phase 1
  2. surzetoclaxphase 1
  3. BTK Degrader ABBV-101phase 1
  4. ABBV-1162phase 1
  5. ABBV-1451phase 1

and 23 more — sign in to see them all

40%
–
Phase 2

AstraZeneca: 47 of its 119 programs at phase 2

  1. AZD9550phase 2
  2. zadavotide guraxetanphase 2
  3. palacaparibphase 2
  4. Berzanoflastphase 2
  5. AZD7798phase 2

and 42 more — sign in to see them all

39%

AbbVie: 20 of its 70 programs at phase 2

  1. ABBV-295phase 2
  2. zumilokibartphase 2
  3. ABBV-932phase 2
  4. trosunilimabphase 2
  5. ABBV-701phase 2

and 15 more — sign in to see them all

29%
–
Phase 3

AstraZeneca: 28 of its 119 programs at phase 3

  1. rilvegostomigphase 3
  2. datopotamab deruxtecanphase 3
  3. tremelimumabphase 3
  4. volrustomigphase 3
  5. Autologous Bispecific BCMA/CD19-targeted CAR-T Cells GC012Fphase 3

and 23 more — sign in to see them all

24%

AbbVie: 16 of its 70 programs at phase 3

  1. telisotuzumab adizutecanphase 3
  2. etentamigphase 3
  3. lutikizumabphase 3
  4. mirvetuximab soravtansinephase 3
  5. turmetabart adizutecanphase 3

and 11 more — sign in to see them all

23%
–
Approved, new studies

AstraZeneca: 19 of its 119 programs at approved, new studies

  1. durvalumabapproved, new study
  2. acalabrutinibapproved, new study
  3. trastuzumab deruxtecanapproved, new study
  4. osimertinibapproved, new study
  5. anifrolumabapproved, new study

and 14 more — sign in to see them all

16%

AbbVie: 6 of its 70 programs at approved, new studies

  1. upadacitinibapproved, new study
  2. risankizumabapproved, new study
  3. venetoclaxapproved, new study
  4. botulinum toxin type Aapproved, new study
  5. atogepantapproved, new study

and 1 more — sign in to see them all

9%
–

Readouts ahead

Programs whose next study reaches primary completion in each month, by the sponsor's own estimate. A ring marks a month with a phase 3 readout.

Nov ’26DecJan ’27FebMarAprMayJunJulAugSepOct
AstraZeneca60 readouts · 16 phase 3

AstraZeneca, Nov ’26: 4 programs whose next study reaches primary completion

  1. Autologous dnTGF-BRII-armored Anti-STEAP2 CAR T-cells AZD0754phase 2 · Nov 24 · NCT06267729
  2. STEAP2-targeting Radioconjugate AZD2287phase 2 · Nov 24 · NCT06267729
  3. durvalumabapproved, new study · Nov 30 · NCT07081633
  4. tremelimumabphase 3 · Nov 30 · NCT07081633

AstraZeneca, Dec ’26: 7 programs whose next study reaches primary completion, 2 in phase 3

  1. eculizumabapproved, new study · Dec 7 · NCT06724809
  2. AZD3974phase 1 · Dec 8 · NCT07290283
  3. baxdrostatphase 3 · Dec 10 · NCT07222917
  4. dapagliflozinapproved, new study · Dec 10 · NCT07222917
  5. benralizumabapproved, new study · Dec 23 · NCT05692180

and 2 more — sign in to see them all

AstraZeneca, Jan ’27: 13 programs whose next study reaches primary completion, 6 in phase 3

  1. laroprovstatphase 3 · Jan 4 · NCT07000136
  2. anifrolumabapproved, new study · Jan 6 · NCT05925803
  3. monalizumabphase 3 · Jan 8 · NCT05221840
  4. oleclumabphase 3 · Jan 8 · NCT05221840
  5. datopotamab deruxtecanphase 3 · Jan 11 · NCT06417814

and 8 more — sign in to see them all

AstraZeneca, Feb ’27: 7 programs whose next study reaches primary completion, 3 in phase 3

  1. Autologous Bispecific BCMA/CD19-targeted CAR-T Cells GC012Fphase 3 · Feb 1 · NCT06530849
  2. trastuzumab deruxtecanapproved, new study · Feb 10 · NCT06271837
  3. Berzanoflastphase 2 · Feb 11 · NCT07215702
  4. acalabrutinibapproved, new study · Feb 15 · NCT02972840
  5. zibotentanphase 3 · Feb 18 · NCT06087835

and 2 more — sign in to see them all

AstraZeneca, Mar ’27: 4 programs whose next study reaches primary completion

  1. AZD7760phase 2 · Mar 8 · NCT06749457
  2. AZD4954phase 1 · Mar 17 · NCT07812077
  3. AZD0543phase 1 · Mar 24 · NCT07824622
  4. Anti-Claudin 18.2 Antibody-drug Conjugate AZD4360phase 2 · Mar 31 · NCT06921928

AstraZeneca, Apr ’27: 3 programs whose next study reaches primary completion, 1 in phase 3

  1. AZD1043phase 1 · Apr 9 · NCT07511205
  2. camizestrantphase 3 · Apr 20 · NCT05774951
  3. ombetoxabartphase 2 · Apr 20 · NCT07285213

AstraZeneca, May ’27: 5 programs whose next study reaches primary completion, 2 in phase 3

  1. rilvegostomigphase 3 · May 4 · NCT04379596
  2. Anti-CD20/Anti-CD3/Anti-CD8 Trispecific Antibody AZD5492phase 2 · May 5 · NCT06916806
  3. AZD1613phase 1 · May 22 · NCT07228364
  4. Budesonideapproved, new study · May 31 · NCT07073950
  5. formoterolapproved, new study · May 31 · NCT07073950

AstraZeneca, Jun ’27: 3 programs whose next study reaches primary completion, 1 in phase 3

  1. tozorakimabphase 3 · Jun 7 · NCT06932263
  2. ravulizumabapproved, new study · Jun 25 · NCT07308574
  3. Anti-GPC3 T Cell-engaging Antibody AZD9793phase 2 · Jun 30 · NCT06795022

AstraZeneca, Jul ’27: 3 programs whose next study reaches primary completion

  1. ALXN1920phase 2 · Jul 2 · NCT07157787
  2. AZD2389phase 2 · Jul 7 · NCT07610837
  3. SC rilvegostomig + rHuphase 1 · Jul 19 · NCT07161414

AstraZeneca, Aug ’27: 4 programs whose next study reaches primary completion

  1. ALXN2230phase 1 · Aug 9 · NCT07352423
  2. AZD0240phase 1 · Aug 30 · NCT06218914
  3. SC durvalumab + rHuphase 1 · Aug 30 · NCT07391670
  4. AZD6793phase 2 · Aug 31 · NCT07082738

AstraZeneca, Sep ’27: 2 programs whose next study reaches primary completion

  1. palacaparibphase 2 · Sep 29 · NCT05123482
  2. puxitatug samrotecanphase 3 · Sep 29 · NCT05123482

AstraZeneca, Oct ’27: 5 programs whose next study reaches primary completion, 1 in phase 3

  1. opemalirsenphase 2 · Oct 4 · NCT06824987
  2. cevolisiranphase 2 · Oct 11 · NCT06744647
  3. tarperprumigphase 2 · Oct 11 · NCT07160608
  4. torvutatug samrotecanphase 3 · Oct 15 · NCT07402915
  5. sodium zirconium cyclosilicateapproved, new study · Oct 30 · NCT07944378
AbbVie34 readouts · 5 phase 3

AbbVie, Nov ’26: 6 programs whose next study reaches primary completion, 1 in phase 3

  1. ABBV-701phase 2 · Nov 0 · NCT06895343
  2. ABBV-932phase 2 · Nov 0 · NCT06846320
  3. mirvetuximab soravtansinephase 3 · Nov 0 · NCT05456685
  4. upadacitinibapproved, new study · Nov 0 · NCT06389136
  5. venetoclaxapproved, new study · Nov 0 · NCT04895436

and 1 more — sign in to see them all

AbbVie, Dec ’26: 4 programs whose next study reaches primary completion, 1 in phase 3

  1. ABBV-295phase 2 · Dec 0 · NCT07514260
  2. emraclidinephase 2 · Dec 0 · NCT07219030
  3. lutikizumabphase 3 · Dec 0 · NCT06468228
  4. telisotuzumab adizutecanphase 3 · Dec 0 · NCT06107413

AbbVie, Jan ’27: 1 program whose next study reaches primary completion

  1. risankizumabapproved, new study · Jan 0 · NCT07466550

AbbVie, Feb ’27: 9 programs whose next study reaches primary completion

  1. [11C]ABBV-112iearly phase 1 · Feb 0 · NCT07933497
  2. ABBV-859phase 1 · Feb 0 · NCT07736638
  3. Anti-CD19-Glucosteroid Receptor Modulator ADC ABBV-31phase 1 · Feb 0 · NCT05512390
  4. etentamigphase 3 · Feb 0 · NCT06223516
  5. MEDI0618phase 2 · Feb 0 · NCT06602479

and 4 more — sign in to see them all

·

AbbVie, Apr ’27: 1 program whose next study reaches primary completion

  1. ABBV-1451phase 1 · Apr 0 · NCT07570147

AbbVie, May ’27: 6 programs whose next study reaches primary completion, 1 in phase 3

  1. ABBV-1162phase 1 · May 0 · NCT07832708
  2. ABBV-243phase 1 · May 0 · NCT07306754
  3. ABBV-7828phase 1 · May 0 · NCT07856706
  4. Anti-PSMA/STEAP1 Antibody-drug Conjugate ABBV-969phase 1 · May 0 · NCT06318273
  5. trosunilimabphase 2 · May 0 · NCT07925983

and 1 more — sign in to see them all

AbbVie, Jun ’27: 1 program whose next study reaches primary completion, 1 in phase 3

  1. botulinum toxin type Aapproved, new study · Jun 0 · NCT07794891

AbbVie, Jul ’27: 4 programs whose next study reaches primary completion

  1. ABBV-1606phase 1 · Jul 0 · NCT07935564
  2. azirkitugphase 1 · Jul 0 · NCT05005403
  3. surzetoclaxphase 2 · Jul 0 · NCT06291220
  4. surzetoclaxphase 1 · Jul 0 · NCT06291220

AbbVie, Aug ’27: 1 program whose next study reaches primary completion, 1 in phase 3

  1. vedolizumabphase 3 · Aug 0 · NCT06880744

AbbVie, Sep ’27: 1 program whose next study reaches primary completion

  1. icalcaprantphase 2 · Sep 0 · NCT07276997
·
Abbott0 readouts · 0 phase 3············
size: programs that monthincludes phase 3Dates are estimates the sponsors file and often move.

Changed in the last 90 days

Since Aug 22, 2026: programs whose first study was registered, programs that reached a new phase, studies stopped, and primary completions moved later (a month or more in phase 3, three otherwise). Stops and dates are read from the registry’s changes, kept since Sep 25, 2026.

AstraZeneca

New programs 2

Reached a new phase 1

Study stopped 0

None

Primary completion later 23

AbbVie

New programs 5

Reached a new phase 1

  • ABBV-722phase 3 · Oct 23 · Scleroderma, Systemic

Study stopped 0

None

Primary completion later 10

Abbott

No programs read for this company.

Where they overlap

Conditions where at least two of them have programs: 34 in all. A program counts in each condition its studies name most.

ConditionAstraZenecaAbbVieAbbott
Carcinoma, Non-Small-Cell Lung2 of 3 · compare here

AstraZeneca in Carcinoma, Non-Small-Cell Lung: 16 programs

  1. rilvegostomigphase 3
  2. datopotamab deruxtecanphase 3
  3. tremelimumabphase 3
  4. volrustomigphase 3
  5. ceralasertibphase 3

and 11 more — sign in to see them all

Their studies: AstraZeneca’s studies of Carcinoma, Non-Small-Cell Lung in search

AbbVie in Carcinoma, Non-Small-Cell Lung: 4 programs

  1. telisotuzumab adizutecanphase 3
  2. ABBV-1480phase 3
  3. azirkitugphase 1
  4. RC148no phase

Their studies: AbbVie’s studies of Carcinoma, Non-Small-Cell Lung in search

–
Prostatic Neoplasms2 of 3 · compare here

AstraZeneca in Prostatic Neoplasms: 13 programs

  1. saruparibphase 3
  2. capivasertibphase 3
  3. zibotentanphase 3
  4. Actinium-225phase 3
  5. zadavotide guraxetanphase 2

and 8 more — sign in to see them all

Their studies: AstraZeneca’s studies of Prostatic Neoplasms in search

–
Breast Neoplasms2 of 3 · compare here

AstraZeneca in Breast Neoplasms: 10 programs

  1. datopotamab deruxtecanphase 3
  2. saruparibphase 3
  3. capivasertibphase 3
  4. camizestrantphase 3
  5. puxitatug samrotecanphase 3

and 5 more — sign in to see them all

Their studies: AstraZeneca’s studies of Breast Neoplasms in search

AbbVie in Breast Neoplasms: 2 programs

  1. trifluridine tipiracil drug combinationphase 3
  2. RC148no phase

Their studies: AbbVie’s studies of Breast Neoplasms in search

–
Asthma2 of 3 · compare here

AstraZeneca in Asthma: 10 programs

  1. tozorakimabphase 3
  2. BFF MDIphase 3
  3. GP MDIphase 3
  4. londamocitinibphase 2
  5. sunakimentphase 2

and 5 more — sign in to see them all

Their studies: AstraZeneca’s studies of Asthma in search

AbbVie in Asthma: 1 program

  1. zumilokibartphase 2

Their studies: AbbVie’s studies of Asthma in search

–
Multiple Myeloma2 of 3 · compare here–
Renal Insufficiency2 of 3 · compare here

AstraZeneca in Renal Insufficiency: 8 programs

  1. elecoglipronphase 3
  2. lenbelintidephase 3
  3. zibotentanphase 3
  4. balcinrenonephase 3
  5. opemalirsenphase 2

and 3 more — sign in to see them all

Their studies: AstraZeneca’s studies of Renal Insufficiency in search

AbbVie in Renal Insufficiency: 2 programs

  1. tavapadonphase 3
  2. emraclidinephase 2

Their studies: AbbVie’s studies of Renal Insufficiency in search

–
Neoplasms2 of 3 · compare here

AstraZeneca in Neoplasms: 6 programs

  1. saruparibphase 3
  2. ceralasertibphase 3
  3. Leucovorinphase 2
  4. Ramucirumabphase 2
  5. AZD1390phase 1

and 1 more — sign in to see them all

Their studies: AstraZeneca’s studies of Neoplasms in search

–
Stomach Neoplasms2 of 3 · compare here

AbbVie in Stomach Neoplasms: 1 program

  1. trifluridine tipiracil drug combinationphase 3

Their studies: AbbVie’s studies of Stomach Neoplasms in search

–
Crohn Disease2 of 3 · compare here

AstraZeneca in Crohn Disease: 1 program

  1. AZD7798phase 2

Their studies: AstraZeneca’s studies of Crohn Disease in search

AbbVie in Crohn Disease: 7 programs

  1. lutikizumabphase 3
  2. vedolizumabphase 3
  3. trosunilimabphase 2
  4. ABBV-701phase 2
  5. ABBV-8736phase 2

and 2 more — sign in to see them all

Their studies: AbbVie’s studies of Crohn Disease in search

–
Leukemia, Lymphocytic, Chronic, B-Cell2 of 3 · compare here

AstraZeneca in Leukemia, Lymphocytic, Chronic, B-Cell: 5 programs

  1. surovatamigphase 3
  2. ceralasertibphase 3
  3. monalizumabphase 3
  4. pirtobrutinibphase 2
  5. acalabrutinibapproved, new study

Their studies: AstraZeneca’s studies of Leukemia, Lymphocytic, Chronic, B-Cell in search

AbbVie in Leukemia, Lymphocytic, Chronic, B-Cell: 3 programs

  1. surzetoclaxphase 2
  2. surzetoclaxphase 1
  3. venetoclaxapproved, new study

Their studies: AbbVie’s studies of Leukemia, Lymphocytic, Chronic, B-Cell in search

–
Arthritis, Rheumatoid2 of 3 · compare here

AstraZeneca in Arthritis, Rheumatoid: 2 programs

  1. surovatamigphase 3
  2. AZD1163phase 2

Their studies: AstraZeneca’s studies of Arthritis, Rheumatoid in search

AbbVie in Arthritis, Rheumatoid: 5 programs

  1. lutikizumabphase 3
  2. ABBV-722phase 3
  3. ravagalimabphase 2
  4. CPTX2309phase 1
  5. upadacitinibapproved, new study

Their studies: AbbVie’s studies of Arthritis, Rheumatoid in search

–
Carcinoma, Hepatocellular2 of 3 · compare here

AstraZeneca in Carcinoma, Hepatocellular: 6 programs

  1. rilvegostomigphase 3
  2. tremelimumabphase 3
  3. Leucovorinphase 2
  4. Anti-GPC3 T Cell-engaging Antibody AZD9793phase 2
  5. Ramucirumabphase 2

and 1 more — sign in to see them all

Their studies: AstraZeneca’s studies of Carcinoma, Hepatocellular in search

AbbVie in Carcinoma, Hepatocellular: 1 program

  1. telisotuzumab adizutecanphase 3

Their studies: AbbVie’s studies of Carcinoma, Hepatocellular in search

–
Colitis, Ulcerative2 of 3 · compare here

AstraZeneca in Colitis, Ulcerative: 1 program

  1. Budesonideapproved, new study

Their studies: AstraZeneca’s studies of Colitis, Ulcerative in search

AbbVie in Colitis, Ulcerative: 4 programs

  1. vedolizumabphase 3
  2. ravagalimabphase 2
  3. upadacitinibapproved, new study
  4. risankizumabapproved, new study

Their studies: AbbVie’s studies of Colitis, Ulcerative in search

–
Endometrial Neoplasms2 of 3 · compare here

AstraZeneca in Endometrial Neoplasms: 4 programs

  1. rilvegostomigphase 3
  2. datopotamab deruxtecanphase 3
  3. puxitatug samrotecanphase 3
  4. trastuzumab deruxtecanapproved, new study

Their studies: AstraZeneca’s studies of Endometrial Neoplasms in search

AbbVie in Endometrial Neoplasms: 1 program

  1. opugotamig olatansinephase 2

Their studies: AbbVie’s studies of Endometrial Neoplasms in search

–
Obesity2 of 3 · compare here

AstraZeneca in Obesity: 4 programs

  1. elecoglipronphase 3
  2. lenbelintidephase 3
  3. AZD9550phase 2
  4. AZD1043phase 1

Their studies: AstraZeneca’s studies of Obesity in search

AbbVie in Obesity: 1 program

  1. ABBV-295phase 2

Their studies: AbbVie’s studies of Obesity in search

–
Squamous Cell Carcinoma of Head and Neck2 of 3 · compare here

AstraZeneca in Squamous Cell Carcinoma of Head and Neck: 3 programs

  1. tremelimumabphase 3
  2. volrustomigphase 3
  3. monalizumabphase 3

Their studies: AstraZeneca’s studies of Squamous Cell Carcinoma of Head and Neck in search

AbbVie in Squamous Cell Carcinoma of Head and Neck: 2 programs

  1. telisotuzumab adizutecanphase 3
  2. ABBV-711phase 1

Their studies: AbbVie’s studies of Squamous Cell Carcinoma of Head and Neck in search

–
Colorectal Neoplasms2 of 3 · compare here

AstraZeneca in Colorectal Neoplasms: 1 program

  1. Leucovorinphase 2

Their studies: AstraZeneca’s studies of Colorectal Neoplasms in search

AbbVie in Colorectal Neoplasms: 3 programs

  1. telisotuzumab adizutecanphase 3
  2. trifluridine tipiracil drug combinationphase 3
  3. RC148no phase

Their studies: AbbVie’s studies of Colorectal Neoplasms in search

–
Dermatitis, Atopic2 of 3 · compare here

AstraZeneca in Dermatitis, Atopic: 1 program

  1. tezepelumabapproved, new study

Their studies: AstraZeneca’s studies of Dermatitis, Atopic in search

AbbVie in Dermatitis, Atopic: 3 programs

  1. zumilokibartphase 2
  2. APG990phase 1
  3. upadacitinibapproved, new study

Their studies: AbbVie’s studies of Dermatitis, Atopic in search

–
Lupus Erythematosus, Systemic2 of 3 · compare here

AbbVie in Lupus Erythematosus, Systemic: 1 program

  1. ABBV-519phase 1

Their studies: AbbVie’s studies of Lupus Erythematosus, Systemic in search

–
Melanoma2 of 3 · compare here

AstraZeneca in Melanoma: 3 programs

  1. tremelimumabphase 3
  2. ceralasertibphase 3
  3. CD8-guided IL-2 Fusion Protein AZD6750phase 2

Their studies: AstraZeneca’s studies of Melanoma in search

AbbVie in Melanoma: 1 program

  1. vedolizumabphase 3

Their studies: AbbVie’s studies of Melanoma in search

–
Ovarian Neoplasms2 of 3 · compare here

AstraZeneca in Ovarian Neoplasms: 2 programs

  1. saruparibphase 3
  2. torvutatug samrotecanphase 3

Their studies: AstraZeneca’s studies of Ovarian Neoplasms in search

–
Small Cell Lung Carcinoma2 of 3 · compare here

AstraZeneca in Small Cell Lung Carcinoma: 2 programs

  1. tremelimumabphase 3
  2. durvalumabapproved, new study

Their studies: AstraZeneca’s studies of Small Cell Lung Carcinoma in search

–
Amyloidosis2 of 3 · compare here

AstraZeneca in Amyloidosis: 2 programs

  1. cliramitugphase 3
  2. acoramidisapproved, new study

Their studies: AstraZeneca’s studies of Amyloidosis in search

AbbVie in Amyloidosis: 1 program

  1. etentamigphase 3

Their studies: AbbVie’s studies of Amyloidosis in search

–
Colonic Neoplasms2 of 3 · compare here

AstraZeneca in Colonic Neoplasms: 2 programs

  1. oleclumabphase 3
  2. monalizumabphase 3

Their studies: AstraZeneca’s studies of Colonic Neoplasms in search

AbbVie in Colonic Neoplasms: 1 program

  1. RC148no phase

Their studies: AbbVie’s studies of Colonic Neoplasms in search

–
Fallopian Tube Neoplasms2 of 3 · compare here

AstraZeneca in Fallopian Tube Neoplasms: 1 program

  1. torvutatug samrotecanphase 3

Their studies: AstraZeneca’s studies of Fallopian Tube Neoplasms in search

AbbVie in Fallopian Tube Neoplasms: 2 programs

  1. mirvetuximab soravtansinephase 3
  2. opugotamig olatansinephase 2

Their studies: AbbVie’s studies of Fallopian Tube Neoplasms in search

–
Hemoglobinuria, Paroxysmal2 of 3 · compare here

AstraZeneca in Hemoglobinuria, Paroxysmal: 2 programs

  1. ravulizumabapproved, new study
  2. eculizumabapproved, new study

Their studies: AstraZeneca’s studies of Hemoglobinuria, Paroxysmal in search

AbbVie in Hemoglobinuria, Paroxysmal: 1 program

  1. pegcetacoplanphase 2

Their studies: AbbVie’s studies of Hemoglobinuria, Paroxysmal in search

–
Lymphoma, Mantle-Cell2 of 3 · compare here

AstraZeneca in Lymphoma, Mantle-Cell: 2 programs

  1. pirtobrutinibphase 2
  2. acalabrutinibapproved, new study

Their studies: AstraZeneca’s studies of Lymphoma, Mantle-Cell in search

AbbVie in Lymphoma, Mantle-Cell: 1 program

  1. venetoclaxapproved, new study

Their studies: AbbVie’s studies of Lymphoma, Mantle-Cell in search

–
Scleroderma, Systemic2 of 3 · compare here

AstraZeneca in Scleroderma, Systemic: 2 programs

  1. Autologous Bispecific BCMA/CD19-targeted CAR-T Cells GC012Fphase 3
  2. anifrolumabapproved, new study

Their studies: AstraZeneca’s studies of Scleroderma, Systemic in search

AbbVie in Scleroderma, Systemic: 1 program

  1. ABBV-722phase 3

Their studies: AbbVie’s studies of Scleroderma, Systemic in search

–
Carcinoma, Ovarian Epithelial2 of 3 · compare here

AstraZeneca in Carcinoma, Ovarian Epithelial: 1 program

  1. torvutatug samrotecanphase 3

Their studies: AstraZeneca’s studies of Carcinoma, Ovarian Epithelial in search

AbbVie in Carcinoma, Ovarian Epithelial: 1 program

  1. mirvetuximab soravtansinephase 3

Their studies: AbbVie’s studies of Carcinoma, Ovarian Epithelial in search

–
Hematologic Neoplasms2 of 3 · compare here

AstraZeneca in Hematologic Neoplasms: 1 program

  1. capivasertibphase 3

Their studies: AstraZeneca’s studies of Hematologic Neoplasms in search

AbbVie in Hematologic Neoplasms: 1 program

  1. BTK Degrader ABBV-101phase 1

Their studies: AbbVie’s studies of Hematologic Neoplasms in search

–
Idiopathic Pulmonary Fibrosis2 of 3 · compare here

AstraZeneca in Idiopathic Pulmonary Fibrosis: 1 program

  1. AZD8965phase 2

Their studies: AstraZeneca’s studies of Idiopathic Pulmonary Fibrosis in search

AbbVie in Idiopathic Pulmonary Fibrosis: 1 program

  1. ABBV-142phase 2

Their studies: AbbVie’s studies of Idiopathic Pulmonary Fibrosis in search

–
Kidney Diseases2 of 3 · compare here

AstraZeneca in Kidney Diseases: 1 program

  1. zibotentanphase 3

Their studies: AstraZeneca’s studies of Kidney Diseases in search

AbbVie in Kidney Diseases: 1 program

  1. trifluridine tipiracil drug combinationphase 3

Their studies: AbbVie’s studies of Kidney Diseases in search

–
Lymphoma, Large B-Cell, Diffuse2 of 3 · compare here

AstraZeneca in Lymphoma, Large B-Cell, Diffuse: 1 program

  1. acalabrutinibapproved, new study

Their studies: AstraZeneca’s studies of Lymphoma, Large B-Cell, Diffuse in search

–
Overweight2 of 3 · compare here

AstraZeneca in Overweight: 1 program

  1. lenbelintidephase 3

Their studies: AstraZeneca’s studies of Overweight in search

AbbVie in Overweight: 1 program

  1. GUB014295phase 1

Their studies: AbbVie’s studies of Overweight in search

–

Same targetBetaPro · free during the beta

Programs that act on the same gene, from the company’s own words, a judged reading of NCIt, ChEMBL or the studies, or a rule. A reading by rule is marked rule.

A target, or a pathogen for a vaccine, known for: AstraZeneca 68 of 119 · AbbVie 54 of 70 · Abbott 0 of 0 programs (42 of them by rule). Most early programs are named only by a code and their companies do not say what they act on, so this list is short and grows as targets are read.

What this can't show

  • Only what ClinicalTrials.gov holds: programs run only in other registries are missing.
  • Grouping is ours: subsidiaries and acquisitions counted under the parent, each dated and sourced on the sponsor page.
  • Readout dates are the sponsors’ estimates, not results.
  • A program is a drug as the registry names it: a code its company has not tied to a name counts on its own until it is read, and a study run under a partner’s name counts for the partner.
  • “Same target” covers only the programs whose target is known, from the company’s words, a judged reading or a rule; most early programs say nothing of it.
  • Programs a company names but has not registered are counted apart (AstraZeneca: 5, AbbVie: 8).